EDINBURGH, Scotland, Jan. 15,
2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that it intends to begin Proof of Concept preclinical studies for
its lead therapeutic TCB008, for treatment in H5N1, commonly known
as "Bird Flu." The Company is currently approaching potential
university partners to expedite the preclinical work required for a
Phase I study.
H5N1 is a viral infection often contracted by contact with sick
birds, yet it can also be passed from person to person. Symptoms
begin within two to eight days and can seem like the common flu,
causing cough, fever, sore throat, muscle aches, headache, and
shortness of breath. The disease can carry a high mortality in
humans. Some antiviral drugs, if taken within two days of symptoms,
may help. Last week, the Louisiana Department of Health recently
reported the first U.S. death from H5N1.
TCB008 is an allogeneic, unmodified cell therapy made up of
activated and expanded gamma delta T (GDT) cells, which the company
expects will have applications in treating the emerging avian bird
flu epidemic. Due to the highly infectious nature of H5N1, TC
BioPharm's goal would be to partner with a leading Infectious
Disease Center or University to advance the Proof-of-Concept and
pre-clinical studies.
"As we have continually noted, we believe that our lead
therapeutic TCB008 has tremendous potential in treating a host of
diseases and infections due to its function within the immune
system," said Bryan Kobel, CEO of TC
BioPharm. "This endeavor further marks TCBP's intent to expand into
indications in the Infectious Disease vertical, with several Proof
of Concept studies planned in multiple infectious
diseases. With the U.S. already incurring its first fatality
and additional cases now confirmed, we want to be aggressive in
working towards a treatment."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on discovering, developing, and commercializing gamma-delta
T-cell therapies for cancer treatment with human efficacy data in
acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute
myeloid leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-h5n1-proof-of-concept-studies-intention-302351044.html
SOURCE TC BioPharm